Trials / Conditions / B-cell Childhood Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia

15 registered clinical trials studyying B-cell Childhood Acute Lymphoblastic Leukemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Par NCT07422337	Arkansas Children's Hospital Research Institute	—
Recruiting	Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT NCT04746209	Medical College of Wisconsin	Phase 2
Unknown	Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia NCT01990807	Chinese Academy of Medical Sciences	Phase 4
Completed	Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia NCT01625143	Children's Oncology Group	—
Completed	Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leuk NCT01540578	Children's Oncology Group	—
Completed	Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia NCT00873093	National Cancer Institute (NCI)	Phase 2
Completed	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529	Fred Hutchinson Cancer Center	Phase 2
Completed	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586	Case Comprehensive Cancer Center	Phase 2
Completed	Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patient NCT00382109	Children's Oncology Group	Phase 3
Completed	Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell NCT00381680	Children's Oncology Group	Phase 3
Terminated	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205	National Cancer Institute (NCI)	Phase 1
Terminated	Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's L NCT00058461	National Cancer Institute (NCI)	Phase 2
Completed	Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methot NCT00898404	Children's Oncology Group	—
Completed	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia NCT00061945	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520	Fred Hutchinson Cancer Center	Phase 1 / Phase 2